Tandem Meetings 2023 | Treatment options for severe and refractory CRS
Kevin McNerney
• 24 Feb 2023
Kevin McNerney, MD, MSc, Johns Hopkins All Children’s Hospital, St. Petersburg, FL, gives an overview of agents that can be used to treat severe cytokine release syndrome (CRS) following treatment with CAR-T therapy. Dr McNerney draws focus on emapalumab, an anti-interferon-gamma antibody, that shows promise in refractory life-threatening CRS. Dr McNerney also comments on the efficacy of siltuximab, anakinra, and ruxolitinib in refractory CRS. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
